Table 1 Patient demographics and clinical characteristics (n = 1326).

From: Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

Characteristics

D-RVD, N = 326 (%)

RVD, N = 1000 (%)

p-value

Median age, years

62.12 (23.5–79.3)

61.21 (16.32–83.05)

 

Age

≤65

220 (67.5)

685 (68.6)

0.794

 

66–70

59 (18.1)

190 (19.1)

 
 

71–75

40 (12.3)

103 (10.3)

 
 

≥76

7 (2.1)

21 (2.1)

 

Gender

Male

181 (55.5)

546 (54.6)

0.441

 

Female

145 (44.5)

454 (45.4)

 

Race

White

180 (55.2)

620 (62)

0.049

 

Black

136 (41.7)

363 (36.3)

 
 

Asian

10 (3.1)

17 (1.7)

 

Isotype

IgG

199 (61.0)

592 (59.2)

 
 

IgA

46 (14.1)

190 (19.0)

 
 

FLC

57 (17.5)

157 (15.7)

 
 

Others

24 (7.4)

61 (6.1)

 

Risk status

Standard

248 (76.1)

633 (63.3)

0.191

 

High

45 (13.8)

251 (25.1)

 
 

Missing

33 (10.1)

116 (11.6)

 

Cytogenetics

t(11;14)

64 (19.6)

121 (12.1)

<0.001

 

Del13

101 (30.9)

240 (24)

0.005

 

1q+

79 (24.2)

152 (15.2)

<0.001

 

t(4;14)

13 (3.9)

45 (4.5)

0.448

 

t(14;16)

3 (0.9)

26 (2.6)

0.054

 

Del17

17 (5.2)

93 (9.3)

0.013

 

Missing

27 (8.3)

66 (6.6)

 

Double hit

Yes

16 (4.9)

58 (5.8)

0.281

 

Missing

33 (10.1)

130 (13)

 

ISS staging

Stage I

128 (39.3)

344 (34.4)

0.466

 

Stage II

78 (23.9)

231 (23.1)

 
 

Stage III

52 (15.9)

176 (17.6)

 
 

Missing

 

249 (24.9)

 

RISS staging

Stage I

114 (34.9)

163 (16.3)

 
 

Stage II

117 (35.8)

199 (19.9)

 
 

Stage III

15 (4.6)

47 (4.7)

 
 

Missing

 

599 (59.9)

 

Transplant

Upfront

311 (95.4)

751 (75.1)

<0.001

 

Deferred

15 (4.6)

168 (16.8)

 

Maintenance

Yes

272 (83.4)

753 (75.3)

0.003

 

No

54 (16.6)

237 (23.7)

 

Labs at diagnosis

Hb < 10

115 (36.4)

343 (34.3)

0.09

 

Plts < 100

15 (4.8)

36 (3.6)

0.44

 

Cr ≥ 2

44 (13.5)

90 (9)

0.014

 

Ca ≥ 10.5

59 (18.8)

121 (12.1)

0.357

 

LDH > 271

23 (9.5)

28 (2.8)

0.109

 

Serum β-2 microglobulin ≥ 5.5

50 (19.2)

117 (11.7)

0.297

Median labs at diagnosis (range)

Hemoglobin

10.9 (4.1–17.9)

10.6 (4.6–18.0)

0.204

 

Platelets

227 (36–613)

218 (20–790)

0.308

 

Serum creatinine

1 (0.4–12.58)

1.07 (0.3–22.5)

0.168

 

Serum calcium

9.5 (4–17.7)

9.4 (5.5–19.2)

0.216

Median time from diagnosis to ASCT (range), months

 

5.7 (3.22–49.6)

6.47 (2.8–145.8)

<0.001

Back to article page